{"filing":{"accession_number":"0001193125-26-431012","cik":"0001121404","ticker":"SNYNF","company_name":"Sanofi","form":"6-K","filing_date":"2026-10-26","report_date":"2026-10-26","primary_document":"d104191d6k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1121404/000119312526431012/d104191d6k.htm"},"events":[{"id":37774,"run_id":34813,"accession_number":"0001193125-26-431012","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces Sanofi's groundbreaking of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production planned for 2032. The disclosure describes a significant capital investment in manufacturing infrastructure and capacity expansion for a core product line (insulin), which is an operational and strategic business event. While the facility represents a material long-term commitment to supply chain resilience and production capacity, it does not fit the specific event types for M\u0026A activity, workforce reduction, or other discrete operational milestones; it is best classified as a material operational/strategic initiative.","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-10-26","form":"6-K","submitted_at":null,"items":[{"id":42602,"accession_number":"0001193125-26-431012","item_number":"EX-99.1","item_title":"d104191dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces Sanofi's groundbreaking of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production planned for 2032. The disclosure describes a significant capital investment in manufacturing infrastructure and capacity expansion for a core product line (insulin), which is an operational and strategic business event. While the facility represents a material long-term commitment to supply chain resilience and production capacity, it does not fit the specific event types for M\u0026A activity, workforce reduction, or other discrete operational milestones; it is best classified as a material operational/strategic initiative.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:42:37.906121+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":42602,"accession_number":"0001193125-26-431012","item_number":"EX-99.1","item_title":"d104191dex991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces Sanofi's groundbreaking of a new state-of-the-art insulin manufacturing facility at its BioCampus in Frankfurt, Germany, with full production planned for 2032. The disclosure describes a significant capital investment in manufacturing infrastructure and capacity expansion for a core product line (insulin), which is an operational and strategic business event. While the facility represents a material long-term commitment to supply chain resilience and production capacity, it does not fit the specific event types for M\u0026A activity, workforce reduction, or other discrete operational milestones; it is best classified as a material operational/strategic initiative.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-10-26T10:42:37.906121+00:00","company_name":"Sanofi","ticker":"SNYNF","filing_date":"2026-10-26"}]}
